Statistical Analysis of COVID-19 Vaccine Effectiveness:A Retrospective Study Based on Global Data
DOI:
https://doi.org/10.62051/8b9wcy88Keywords:
COVID-19; vaccine effectiveness; statistical analysis.Abstract
The COVID-19 pandemic has led to extensive global vaccination campaigns aimed at reducing infection rates, hospitalizations, and mortality. However, disparities in vaccine distribution and the emergence of new variants have raised concerns about real-world vaccine effectiveness across different populations. This paper evaluates the relationship between vaccination rates and public health outcomes, including infection rates, hospitalization rates, and mortality rates, across 15 countries spanning high-, middle-, and low-income regions. Results indicate a strong negative correlation between vaccination rates and severe COVID-19 outcomes, with mRNA vaccines (Pfizer-BioNTech, Moderna) exhibited superior protection. Additionally, countries with early booster rollouts exhibited 30% lower hospitalization rates than those with delayed booster programs.These findings highlight the critical role of vaccination campaigns, the necessity of booster doses for sustained immunity, and the urgent need for equitable vaccine distribution to mitigate global health disparities.
Downloads
References
[1] World Health Organization (WHO). WHO COVID-19 Dashboard. Retrieved, 2023.
[2] Polack, F. P., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. New England Journal of Medicine, 2020, 383(27), 2603-2615. DOI: https://doi.org/10.1056/NEJMoa2034577
[3] Baden, L. R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine,2021, 384(5), 403-416.
[4] Jara,A., et al .Effectiveness ofan Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine, 2021,385(10), 875-884. DOI: https://doi.org/10.1056/NEJMoa2107715
[5] Voysey, M., et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis in Brazil, South Africa, and the UK. The Lancet, 2021, 397(10269), 99-111.
[6] Dagan, N., et al. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine, 2021, 384(15), 1412-1423. DOI: https://doi.org/10.1056/NEJMoa2101765
[7] Mathieu, E., et al. A Global Database of COVID-19 Vaccinations. Nature Human Behaviour, 2021, 5(7), 947-953. DOI: https://doi.org/10.1038/s41562-021-01122-8
[8] Watson, O. J., et al. Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modeling Study. Lancet Infectious Diseases,2022, 22(9), 1293-1302. DOI: https://doi.org/10.1016/S1473-3099(22)00320-6
[9] Thompson, M. G., et al. Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Healthcare Workers. Morbidity and Mortality Weekly Report (MMWR), 2021, 70(13), 495-500.
[10] Lin, D.Y., et al. Effectiveness of Bivalent Boosters Against Severe Omicron Infection. New England Journal of Medicine, 2023, 388(8), 764-766. DOI: https://doi.org/10.1056/NEJMc2215471
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
